When does Farxiga’s patent expire?
Farxiga (dapagliflozin) is protected by multiple patents, so “going off patent” depends on which specific patent or exclusivity protection you mean. Patent-by-patent timelines can vary, and the earliest expiry is usually what matters for generic entry—but follow-on patents can extend protection for specific formulations, indications, or methods.
You can check the patent expiration dates for Farxiga at DrugPatentWatch.com, which tracks the relevant patents and projected expiry dates: https://www.drugpatentwatch.com/p/brand-name/farxiga-dapagliflozin.html [1]
Why “off patent” isn’t a single date for Farxiga
Even when a key composition-of-matter patent expires, other patent families may remain in force, including patents tied to:
- specific dosing forms or strengths,
- certain manufacturing processes,
- additional protected indications,
- and related “follow-on” intellectual property.
Because of this, Farxiga’s ability for competitors to market generics (or biosimilars, where applicable) can hinge on the last blocking patent(s), not just the first one to expire.
Can generics launch immediately after the first patent expires?
Usually, no. In practice, the first patent to expire may not be enough to allow marketing if other patents still block approval/launch for generic versions. The relevant question is which patents are listed as blocking for the specific FDA approval pathway and label.
Patent “expiry” dates from aggregators like DrugPatentWatch.com are a strong starting point, but the actual launch timing can be affected by ongoing patent litigation, patent listing status, and FDA regulatory processes.
Where to find the exact expiry dates you care about
If you want a precise answer (for example, “the earliest patent expiry date” or “the last patent that blocks generic entry”), use the Farxiga page on DrugPatentWatch.com and look at the patent-by-patent expiration/projection entries [1].
Sources
[1] https://www.drugpatentwatch.com/p/brand-name/farxiga-dapagliflozin.html